Clinical trials have shown that HIV-positive preg nant women treated with zidovudine during preg nancy and delivery have a much lower rate of HIV transmission to their newborns. Recent studies have also shown the effectiveness of antiretroviral therapy combined with elective cesarean delivery and a short- term antiretroviral therapy. In this study a dynamic computer model was built. The model was used to estimate economic consequences of testing pregnant women for HIV virus and treating the HIV-positive women and their newborns with three different reg imens. Outcomes of data analysis included costs and the number of avoided cases of perinatal transmission of the HIV virus. The study found that while the over all costs of the three treatment programs were simi lar, the short-term antiretroviral program was the least cost-effective and prevented fewer cases of peri natal transmission of the virus. Sensitivity analysis found that the cost-effectiveness of the treatment pro grams were differentially sensitive to screening and treatment rates. Cost-effectiveness of all regimens is highly sensitive to the HIV infection rate among preg nant women. When the rate reaches four to five per 1,000, treatment cost savings from the reduction in pediatric HIVcases exceed the costs of screening and treatment. The model presented provides a useful tool to be used to evaluate treatment programs designed to pre vent mother-to-infant transmission of the HIV virus.
Unaids.Report on the Global HIV/AIDS Epidemic, World Health Organization , Geneva, 1998.
2.
Wortley, P.M. and Fleming, P.L. "AIDS in Women in the United States: Recent Trends." Journal of the American Medical Association, Vol. 278, pp 911-916, 1997.
3.
National Center for Health Statistics."Annual Summary of Births, Marriages, Divorces and Deaths: United States, 1993." Monthly Vital Statistics Report, Vol. 42, No. 13, pp 18-20, 1994.
4.
Centers for Disease Control and Prevention.National HIV Serosurveillance Summary: Results Through 1992. USDHHS, Public Health Service, Vol. 3, Atlanta, GA, 1994.
5.
Gwinn, M., Wasser, S., Fleming, P., Karon, J. and Peterson, L. "Increasing Prevalence of HIV Infection Among Childbearing Women, United States, 1989-1991." Program and Abstracts of the Ninth International Conference on AIDS, June 6- 11, 1993, Berlin, Germany, abstract no. PO-C16-2990, 1993.
6.
Gwinn, M., Pappaioanou, M., George, J.R., et al. "Prevalence of HIV Infection in Childbearing Women in the United States." Journal of American Medical Association, Vol. 265, pp 1704-1708, 1991.
7.
Indiana State Department of Health, Division of HIV /STD. HIV/STD Quarterly Report, Indianapolis, IN, April 1996.
8.
Frederick, T., Mascola, L., Eller, A., et al. "Progression of Human Immunodeficiency Virus Disease among Infants and Children Infected Perinatally with Human Immunodeficiency Virus or Through Neonatal Blood Transfusion." Pediatric Infectious Disease Journal, Vol. 13, pp 1091-1097, 1994 .
9.
The European Collaborative Study. "Natural History of Vertically Acquired Human Immunodeficiency Virus-1 Infection." Pediatrics, Vol. 94, pp 815-819, 1994.
10.
Landesman, S.H., Minkoff, H.L. and Willoughby , A. "A Human Immunodeficiency Virus Disease in Reproductive Age Women: A Problem of the Present." Journal of the American Medical Association, Vol. 261, pp 1326-1327, 1989.
11.
Connor, E.M. , Sperling, R.S., Gelber, R., et al. for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. "Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment." New England Journal of Medicine, Vol. 331, pp 1173-1180, 1994.
12.
Centers for Disease Control and Prevention."U.S. Public Health Service Recommendations for Human Immunodeficiency Virus Counseling and Voluntary Testing for Pregnant Women." Morbidity and Mortality Weekly Report, Vol. 44 (RR-7), pp 1-15, 1995.
13.
Mandelbrot, L. , Le Chenadec, J., Berrebi, A., et al. "Perinatal HIV-1 Transmission: Interaction between Zidovudine Prophylaxis and Mode of Delivery in the French Perinatal Cohort." Journal of the American Medical Association, Vol. 280, pp 55-60, 1998.
14.
Centers for Disease Control and Prevention."Administration of Zidovudine During Late Pregnancy and Delivery to Prevent Perinatal HIV Transmission—Thailand, 1996-1998." Morbidity and Mortality Weekly Report, Vol. 47, No. 8, pp 152-154,1998.
15.
Brandeau, M.L. , Owens, D.K., Sox, C.H. and Wachter, R.M. "Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Cost-Benefit Analysis." Archives of Internal Medicine, Vol. 152, pp 2229-2237, 1992 .
16.
Brandeau, M.L. , Owens, D.K., Sox, C.H. and Wachter, R.M. "Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis." Management Science, Vol. 39, pp 72-92, 1992.
17.
Nakchbandi, I.A., Longenecker, J.C., Ricksecker, M.A., et al. "A Decision Analysis of Mandatory Compared with Voluntary HIV Testing in Pregnant Women." Annals of Internal Medicine, Vol. 128, pp 760-767, 1998.
18.
Mauskopf, J.A., Paul, J.E., Wichman, D.S., White, A.D. and H.H. Tilson. "Economic Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns with Zidovudine." Journal of the American Medical Association, Vol. 276, pp 132-138, 1996.
19.
Anderson, J.G. and Anderson, M. "Predicting the Economic Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns." Proceedings of 1998 Medical Sciences Simulation Conference, J. G. Anderson and M. Katzper , editors, San Diego, CA, pp 52-57, 1998.
20.
Hannon, B. and Ruth, M.Dynamic Modeling, Springer-Verlag, NY, 1994.
21.
U.S. Bureau of the Census.Statistical Abstract of the United States: 1996, Washington, DC, 1996.
22.
Hardy, L. M., editor. HIV Screening of Pregnant Women and Newborns. Washington, DC , Committee on Prenatal and Newborn Screening for HIV Infection, Institute of Medicine, National Academy Press, 1991.
23.
Anderson, J.G., Anderson, M. and Booth, T.1997. "Preventing Maternal-Infant Transmission of HIV: Social and Ethical Issues." The Health Education Monograph Series, Vol. 15, No. 2, pp 1-9, 1997.
24.
Cozen, W. , Mascola, L., Enguidanos, R., et al. "Screening for HIV and Hepatitis B Virus in Los Angeles County Prenatal Clinics: A Demonstration Project." Journal of Acquired Immune Deficiency Syndrome, Vol. 6, pp 95-98, 1993.
25.
Centers for Disease Control and Prevention."Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States ." Morbidity and Mortality Weekly Report, 47(RR-2), pp 1-30, 1998.
26.
Centers for Disease Control and Prevention."Recommendations for the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus." Morbidity and Mortality Weekly Report, Vol. 43(RR-11), pp 1-20, 1994.
27.
Parenthood Web Page, Cesarean Fact Sheet at http://www.parenthoodweb.com/parent_cfmfiles/pros.cfm/374
28.
Hsia, D., Fleishman, J., East, J. and Hellinger, F. "Pediatric Human Immunodeficiency Virus Infection." Archives of Pediatric Adolescent Medicine, Vol. 149, pp 489-496, 1995.
29.
Barbacci, M., Repke, J.T. and Chaisson, R.E. "Routine Prenatal Screening for HIV Infection ." Lancet, Vol. 337, pp 709-711,1991.
30.
Working Group on HIV Testing of Pregnant Women and Newborns."HIV Infection, Pregnant Women and Newborns ." Journal of the American Medical Association, Vol. 264, pp 2416-2420, 1990.
31.
Indiana State Department of Health, Division of HIV/STD. HIV/STD Quarterly Report, Indianapolis, IN, January 1996.
32.
Indiana State Department of Health, Division of HIV/STD. HIV/STD Quarterly Report, Indianapolis, IN, July 1997.
